MDGL analyst estimates

Madrigal Pharma (MDGL) analyst ratings, the average price target and its range, and every firm's latest call.

MDGL analyst ratings and price targets

DateFirmCallTarget
Oct 29, 2026B.Riley FinancialB.Riley Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)$670.00
Oct 14, 2026UBSMadrigal Pharmaceuticals (MDGL) PT Raised to $735 at UBS$735.00
Sep 24, 2026Goldman SachsMadrigal Pharmaceuticals resumed with a Buy at Goldman Sachs$704.00
Aug 4, 2026Wolfe ResearchMadrigal upgraded to Outperform from Peer Perform at Wolfe Research$605.00
Jul 31, 2026BarclaysMadrigal Pharmaceuticals (MDGL) PT Lowered to $962 at BarclaysMember Login$962.00
Jul 29, 2026Canaccord GenuityMadrigal Pharmaceuticals price target raised to $587 from $578 at Canaccord$587.00
Jul 27, 2026Wells FargoMadrigal Pharmaceuticals initiated with an Overweight at Wells Fargo$685.00
Jun 11, 2026Morgan StanleyMadrigal Pharmaceuticals (MDGL) PT Lowered to $542 at BofA Securities$542.00
May 13, 2026Truist FinancialMadrigal Pharmaceuticals price target raised to $709 from $640 at Truist$709.00
May 7, 2026Canaccord GenuityMadrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord$578.00
May 7, 2026Evercore ISIMadrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI$649.00
Jan 27, 2026BarclaysMadrigal Pharmaceuticals initiated with an Overweight at Barclays$964.00
Jan 14, 2026Goldman SachsGoldman Sachs Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)$571.00
Jan 6, 2026Wolfe ResearchWolfe downgrades Madrigal Pharmaceuticals to Peer Perform on valuation$579.00
Dec 19, 2025Piper SandlerMadrigal Pharmaceuticals (MDGL) PT Raised to $900 as Piper Sandler Recommends Buy$900.00

Updated 2026-11-02 23:10 UTC